A study of 790 patients with advanced pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CC) reveals strong mutation concordance (MCR) between circulating tumor DNA (ctDNA) and tissue next-generation sequencing (NGS). In PDAC, 65.4% showed shared alterations, while CC had 66.7%. Additionally, ctDNA could signal resistant clones: increased TP53 variant frequencies correlated with a greater likelihood of disease progression (OR 7.28). This positions ctDNA as a critical tool for diagnosis and monitoring.
Journal Article by Mahadevia H, Majeed U (…) Babiker H et 21 al. in JAMA Netw Open